Laboratorio Reig Jofre, S.A. (RJF.MC)
- Previous Close
3.1000 - Open
3.1200 - Bid 3.0600 x --
- Ask 3.1100 x --
- Day's Range
3.0600 - 3.1200 - 52 Week Range
2.4600 - 3.3800 - Volume
506 - Avg. Volume
37,481 - Market Cap (intraday)
248.223M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
23.85 - EPS (TTM)
0.1300 - Earnings Date Jul 25, 2025
- Forward Dividend & Yield 0.05 (1.58%)
- Ex-Dividend Date May 15, 2025
- 1y Target Est
--
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. The company offers nutritional and parapharmacy products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women's health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services. It sells its products through business partners. The company was founded in 1929 and is headquartered in Barcelona, Spain. Laboratorio Reig Jofre, S.A. operates as a subsidiary of Reig Jofre Investments SL.
www.reigjofre.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: RJF.MC
View MorePerformance Overview: RJF.MC
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RJF.MC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RJF.MC
View MoreValuation Measures
Market Cap
248.22M
Enterprise Value
290.67M
Trailing P/E
23.85
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.73
Price/Book (mrq)
1.16
Enterprise Value/Revenue
0.86
Enterprise Value/EBITDA
8.03
Financial Highlights
Profitability and Income Statement
Profit Margin
3.09%
Return on Assets (ttm)
2.73%
Return on Equity (ttm)
5.01%
Revenue (ttm)
338.9M
Net Income Avi to Common (ttm)
10.47M
Diluted EPS (ttm)
0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
23M
Total Debt/Equity (mrq)
27.48%
Levered Free Cash Flow (ttm)
--